Losartan Potassium
NDC Package 53808-0896-1

11-digit billing NDC: 53808089601

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Losartan Potassium is hypertensionLosartan potassium tablets are indicated for the treatment of hypertension. Marketed by State Of Florida Doh Central Pharmacy, this product is identified by NDC 53808-0896 and is authorized under FDA application ANDA090428.

Identification & Billing

NDC Package Code
53808-0896-1
Package Description
30 TABLET, FILM COATED in 1 BLISTER PACK
Product Code
11-Digit Billing Format
53808089601
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Losartan Potassium
Dosage Form
-
Usage Information
HypertensionLosartan potassium tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents, including diuretics. Hypertensive Patients with Left Ventricular HypertrophyLosartan potassium tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients (see PRECAUTIONS, Race and CLINICAL PHARMACOLOGY, Pharmacodynamics and Clinical Effects, Reduction in the Risk of Stroke, Race).Nephropathy in Type 2 Diabetic PatientsLosartan potassium tablets are indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥300 mg/g) in patients with type 2 diabetes and a history of hypertension. In this population, losartan potassium tablets reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease (need for dialysis or renal transplantation) (see CLINICAL PHARMACOLOGY, Pharmacodynamics and Clinical Effects).

Regulatory & Marketing

Labeler Name
State Of Florida Doh Central Pharmacy
FDA Application #
ANDA090428
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
01-01-2014
Listing Expiration
12-31-2017
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 53808-0896-1 identifies a specific commercial package of 30 tablet, film coated in 1 blister pack of Losartan Potassium, labeled by State Of Florida Doh Central Pharmacy. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by State Of Florida Doh Central Pharmacy on January 01, 2014. The current certification is valid through December 31, 2017.

How is this State Of Florida Doh Central Pharmacy product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 53808089601. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
53808-0896-1
11-Digit CMS (5-4-2)
53808-0896-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.